These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16567376)

  • 1. Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis.
    Claassen JA; Jansen RW
    J Gerontol A Biol Sci Med Sci; 2006 Mar; 61(3):267-71. PubMed ID: 16567376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cerebrovascular role of the cholinergic neural system in Alzheimer's disease.
    Van Beek AH; Claassen JA
    Behav Brain Res; 2011 Aug; 221(2):537-42. PubMed ID: 20060023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement.
    Brousseau G; Rourke BP; Burke B
    Exp Clin Psychopharmacol; 2007 Dec; 15(6):546-54. PubMed ID: 18179307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A second wind for the cholinergic system in Alzheimer's therapy.
    Douchamps V; Mathis C
    Behav Pharmacol; 2017 Apr; 28(2 and 3-Spec Issue):112-123. PubMed ID: 28240674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinesterase inhibitors: A new class of psychotropic compounds.
    Cummings JL
    Am J Psychiatry; 2000 Jan; 157(1):4-15. PubMed ID: 10618007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: data from the ICTUS study.
    Canevelli M; Adali N; Kelaiditi E; Cantet C; Ousset PJ; Cesari M;
    Phytomedicine; 2014 May; 21(6):888-92. PubMed ID: 24548724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrovascular Pathology and Responsiveness to Treatment in Alzheimer's Disease: A Systematic Review.
    Bentham C; De Marco M; Venneri A
    Curr Alzheimer Res; 2021; 18(2):103-124. PubMed ID: 33855943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia.
    Román GC; Kalaria RN
    Neurobiol Aging; 2006 Dec; 27(12):1769-85. PubMed ID: 16300856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of functional hyperemia to visual stimulation in mild Alzheimer's disease and its sensitivity to cholinesterase inhibition.
    Janik R; Thomason LA; Chaudhary S; Dorr A; Scouten A; Schwindt G; Masellis M; Stanisz GJ; Black SE; Stefanovic B
    Biochim Biophys Acta; 2016 May; 1862(5):957-65. PubMed ID: 26521151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cortical oxygen supply during postural hypotension is further decreased in Alzheimer's disease, but unrelated to cholinesterase-inhibitor use.
    van Beek AH; Sijbesma JC; Jansen RW; Rikkert MG; Claassen JA
    J Alzheimers Dis; 2010; 21(2):519-26. PubMed ID: 20555135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
    Lane RM; Potkin SG; Enz A
    Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinergic enhancement increases regional cerebral blood flow to the posterior cingulate cortex in mild Alzheimer's disease.
    Iizuka T; Kameyama M
    Geriatr Gerontol Int; 2017 Jun; 17(6):951-958. PubMed ID: 27215917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease.
    Haywood WM; Mukaetova-Ladinska EB
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):273-86. PubMed ID: 17062329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model.
    Ongali B; Nicolakakis N; Tong XK; Aboulkassim T; Papadopoulos P; Rosa-Neto P; Lecrux C; Imboden H; Hamel E
    Neurobiol Dis; 2014 Aug; 68():126-36. PubMed ID: 24807206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer's Disease.
    Wang H; Zhang H
    ACS Chem Neurosci; 2019 Feb; 10(2):852-862. PubMed ID: 30521323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinergic therapy for neuropsychiatric symptoms in neurologic disorders.
    Kaufer DI
    Curr Psychiatry Rep; 1999 Oct; 1(1):78-84. PubMed ID: 11122908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinergic foundations of Alzheimer's disease therapy.
    Giacobini E
    J Physiol Paris; 1998; 92(3-4):283-7. PubMed ID: 9789824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Cognitive Deficits in Alzheimer's disease: A psychopharmacological review.
    Campos C; Rocha NB; Vieira RT; Rocha SA; Telles-Correia D; Paes F; Yuan T; Nardi AE; Arias-Carrión O; Machado S; Caixeta L
    Psychiatr Danub; 2016 Mar; 28(1):2-12. PubMed ID: 26938815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy.
    Paterson RW; Abdi Z; Haines A; Schott JM
    Clin Neurol Neurosurg; 2016 May; 144():64-6. PubMed ID: 26989943
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacology and clinical efficacy of cholinesterase inhibitors.
    Jann MW
    Am J Health Syst Pharm; 1998 Nov; 55 Suppl 2():S22-5. PubMed ID: 9809108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.